Nano4Imaging

About Nano4Imaging

Nano4Imaging (N4I) is an innovation leader in developing software and devices for interventional MRI (iMRI) based on nanotechnology and artificial intelligence. The company offers a groundbreaking technology platform — navigation software, MRI markers, and devices — enabling MRI for endovascular interventions in real-time. The advantages over X-ray/CT imaging are more precise and safer interventions. Emery Glide, the first MRI-compatible guidewire, has been FDA-approved and successfully used to treat over 200 patients. The market for interventional MRI will grow strongly (CAGR 24%) to $2.3 billion by 2030. This growth is driven by the strengths of MR imaging: superior soft tissue visualization and real-time theranostic capabilities. In addition, harmful radiation and contrast agents can be avoided. N4I's tracker technology focuses on 10 indications with a volume of over 500,000 procedures. N4I’s products are sold to hospitals and MRI system manufacturers, providing over $500 million in revenue potential. N4I has raised $12.5 million in seed capital and is seeking $6 million in Series A funding. It has already secured 50% of this funding